NCT00211354View on ClinicalTrials.gov

Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2002

Primary Completion Date

March 31, 2007

Study Completion Date

April 30, 2007

Conditions
Retinal Vein Occlusion
Interventions
DRUG

Anecortave Acetate

ancortave acetate 15 mg. juxtascleral injection every 6 months for 24 months.

Trial Locations (1)

10021

Manhattan Eye, Ear & Throat Hospital, New York

Sponsors

Collaborators (1)

Alcon Research
All Listed Sponsors
collaborator

Alcon Research

INDUSTRY

lead

Manhattan Eye, Ear & Throat Hospital

OTHER